Incremental net benefit of whole genome sequencing for newborns and children with suspected genetic disorders: Systematic review and meta-analysis of cost-effectiveness evidence.

[1]  W. V. van Harten,et al.  Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer , 2021, PharmacoEconomics.

[2]  Aashish N. Adhikari,et al.  The Use of Whole Genome and Exome Sequencing for Newborn Screening: Challenges and Opportunities for Population Health , 2021, Frontiers in Pediatrics.

[3]  A. Thakkinstian,et al.  Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences , 2021, Obesity Surgery.

[4]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[5]  S. Biskup,et al.  The question of WGS’s clinical utility remains unanswered , 2021, European Journal of Human Genetics.

[6]  I. Dhalla,et al.  Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies , 2020, Genetics in Medicine.

[7]  K. Kandaswamy,et al.  Successful application of genome sequencing in a diagnostic setting: 1007 index cases from a clinically heterogeneous cohort , 2020, European journal of human genetics : EJHG.

[8]  Christine Y. Lu,et al.  Ending the Diagnostic Odyssey-Is Whole-Genome Sequencing the Answer? , 2020, JAMA pediatrics.

[9]  K. Girisha,et al.  Genomic Testing for Diagnosis of Genetic Disorders in Children: Chromosomal Microarray and Next—Generation Sequencing , 2020, Indian Pediatrics.

[10]  V. Jobanputra,et al.  The Medical Genome Initiative: moving whole-genome sequencing for rare disease diagnosis to the clinic , 2020, Genome Medicine.

[11]  T. Anothaisintawee,et al.  Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  L. Lynd,et al.  The cost trajectory of the diagnostic care pathway for children with suspected genetic disorders , 2019, Genetics in Medicine.

[13]  Alicia Guemez-Gamboa,et al.  Genetic Causes and Modifiers of Autism Spectrum Disorder , 2019, Front. Cell. Neurosci..

[14]  B. Dallapiccola,et al.  Cost-effectiveness of exome sequencing: an Italian pilot study on undiagnosed patients , 2019, New Genetics and Society.

[15]  S. Youngkong,et al.  Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus Vaccine in Low-Income and Lower-Middle-Income Countries , 2019, Open forum infectious diseases.

[16]  Sri V. V. Deevi,et al.  Whole genome sequencing reveals that genetic conditions are frequent in intensively ill children , 2019, Intensive Care Medicine.

[17]  Denise L. Perry,et al.  Clinical whole genome sequencing as a first-tier test at a resource-limited dysmorphology clinic in Mexico , 2019, npj Genomic Medicine.

[18]  Faye L. Bowman,et al.  The Evolution of Public Health Genomics: Exploring Its Past, Present, and Future , 2018, Front. Public Health.

[19]  S. Kingsmore,et al.  Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases , 2018, npj Genomic Medicine.

[20]  P. Szatmari,et al.  Cost-effectiveness of Genome and Exome Sequencing in Children Diagnosed with Autism Spectrum Disorder , 2018, Applied Health Economics and Health Policy.

[21]  J. Mattick,et al.  Whole genome sequencing provides better diagnostic yield and future value than whole exome sequencing , 2018, The Medical journal of Australia.

[22]  S. Kingsmore,et al.  Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization , 2018, npj Genomic Medicine.

[23]  Barton E Slatko,et al.  Overview of Next‐Generation Sequencing Technologies , 2018, Current protocols in molecular biology.

[24]  Jenny C. Taylor,et al.  Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature , 2018, Genetics in Medicine.

[25]  Michael Brudno,et al.  Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray , 2017, European Journal of Human Genetics.

[26]  G. Iskrov,et al.  Whole-Genome Sequencing in Newborn Screening—Attitudes and Opinions of Bulgarian Pediatricians and Geneticists , 2017, Front. Public Health.

[27]  Clara Gaff,et al.  Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions , 2017, JAMA pediatrics.

[28]  Daniele Merico,et al.  A microcosting and cost–consequence analysis of clinical genomic testing strategies in autism spectrum disorder , 2017, Genetics in Medicine.

[29]  S. Eckermann.  Principles and Practice for Trial-Based Health Economic Analysis , 2017 .

[30]  Rémy Bruggmann,et al.  Clinical sequencing: is WGS the better WES? , 2016, Human Genetics.

[31]  B. Fernandez,et al.  Utility of whole‐exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care , 2015, Clinical genetics.

[32]  N. Johnson.  Whole-exome sequencing in neurologic practice , 2015, Neurology: Genetics.

[33]  Y. Dundar,et al.  A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children. , 2015, Health technology assessment.

[34]  Karl Claxton,et al.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.

[35]  Lei Shang,et al.  Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants , 2014, Proceedings of the National Academy of Sciences.

[36]  C. Crespo,et al.  Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies , 2014, BMC Medical Research Methodology.

[37]  R. Eils,et al.  Genome sequencing: a systematic review of health economic evidence , 2013, Health Economics Review.

[38]  M. Dolled-Filhart,et al.  Personalizing rare disease research: how genomics is revolutionizing the diagnosis and treatment of rare disease. , 2012, Personalized medicine.

[39]  Peter Saffrey,et al.  Rapid Whole-Genome Sequencing for Genetic Disease Diagnosis in Neonatal Intensive Care Units , 2012, Science Translational Medicine.

[40]  B. Tarini,et al.  Ethical issues with newborn screening in the genomics era. , 2012, Annual review of genomics and human genetics.

[41]  Leslie G. Biesecker,et al.  Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project , 2012, Genetics in Medicine.

[42]  R. Legood,et al.  Economic evaluation of strategies for managing women with equivocal cytological results in Brazil , 2011, International journal of cancer.

[43]  S. Goldie,et al.  Mathematical models of cervical cancer prevention in the Asia Pacific region. , 2008, Vaccine.

[44]  C. Dewa,et al.  A Clinician's Guide to Correct Cost-Effectiveness Analysis: Think Incremental Not Average , 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[45]  A. Brand,et al.  The impact of genetics and genomics on public health , 2008, European Journal of Human Genetics.

[46]  C. Doran.  Economic evaluation of interventions for illicit opioid dependence: a review of evidence , 2008 .

[47]  Jeremy D Goldhaber-Fiebert,et al.  Cost-effectiveness of HPV 16, 18 vaccination in Brazil. , 2007, Vaccine.

[48]  Sue J Goldie,et al.  Cost-effectiveness of cervical-cancer screening in five developing countries. , 2005, The New England journal of medicine.

[49]  R. Willke,et al.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[50]  Andrew R Willan,et al.  Incremental net benefit in the analysis of economic data from clinical trials, with application to the CADET-Hp trial. , 2004, European journal of gastroenterology & hepatology.

[51]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[52]  Niklas Zethraeus,et al.  Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies , 2003, PharmacoEconomics.

[53]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[54]  Statistical handling of data in economic analysis , 2022 .